O. Osiyemi

Safety and exposure of once‐daily ritonavir‐boosted atazanavir in HIV‐infected pregnant women

R. Bertz, C. Zorrilla, T. Eley, 2011, HIV medicine.

Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96‐week results from two randomized clinical trials†

H. Stellbrink, M. Das, E. Daar, 2018, HIV medicine.

Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily

J. Mrus, P. Verboven, S. Yasin, 2013, HIV medicine.

Reduced exposure to darunavir and cobicistat in HIV‐1‐infected pregnant women receiving a darunavir/cobicistat‐based regimen

H. Crauwels, K. Brown, C. Bicer, 2019, HIV medicine.

Pharmacokinetics of once‐daily darunavir/ritonavir in HIV‐1–infected pregnant women

H. Crauwels, P. Verboven, V. Hillewaert, 2016, HIV medicine.